

Summary of Utilization Management (UM) Program Changes

May 2021

Brand Name	Generic Name	Utilization Update Summary	Type	Effective Date
<i>Kesimpta</i> <i>Zeposia</i> <i>Ponvory</i> <i>in Multiple Sclerosis Agents</i>	ofatumumab ozanimod ponesimod	Kesimpta and Zeposia have been added to the Commercial formulary and no longer require a trial of another drug. Ponvory has been added to the guideline. It will require a trial of only two of the formulary agents or for continuation of therapy.	Update	7/1/2021
<i>Tysabri</i>	natalizumab	For use in Multiple Sclerosis, the requirement of a trial of one formulary drug has the added possibilities of Kesimpta and Zeposia.	Update	7/1/2021